In short
Clinical trials are investigating HUPERZINE A in adults with focal onset seizures. This article explains what the study is testing, who may take part, and which outcomes are being measured, such as seizure frequency and treatment effect.
Key points
- Clinical trials are investigating HUPERZINE A in adults with focal onset seizures. The available study is a Phase 2, double-blind, placebo-controlled trial. It is designed to test whether HUPERZINE A can reduce seizure frequency over time. The study plans to enroll 45 participants. The main outcome is the percent change in focal onset seizure frequency per 28 days during the maintenance period. The trial is authorised and uses oral doses of HUPERZINE A compared with capsules.
Trial overview
The available clinical trial is studying HUPERZINE A in adults with focal onset seizures.
The study is designed to evaluate whether HUPERZINE A may help reduce seizure frequency in this patient group.
Study design and treatment groups
This is a Phase 2 trial, which means it is a later early-stage study that looks at whether a treatment may work in a specific condition.
The study is double-blind and placebo-controlled.
Double-blind means the participants and the study team do not know who receives which treatment, and placebo-controlled means some participants receive capsules without the active study drug.
The intervention list includes oral HUPERZINE A at 0.25 mg, 0.50 mg, and 1.00 mg, as well as capsules used for comparison.
Who can participate
The trial is for adult participants with focal onset seizures.
No other participation details are provided in the source data, so the full eligibility rules cannot be described here.
What the study is measuring
The primary outcome is the percent change from baseline in focal onset seizure frequency per 28 days during the maintenance period.
This means the researchers will compare the number of seizures before treatment with the number during the study period to see whether seizures become less frequent.
The brief summary says the goal is to evaluate the efficacy of SPN-817 as a treatment for adult participants with focal onset seizures.
Trial status and size
The study status is Authorised.
The planned enrollment is 45 people, which means the study is designed to include 45 participants.
Because only one trial is listed in the source data, this article reflects a very limited trial set and focuses on the main details available for that study.